dihydroxyphenylalanine

Summary

Summary: A beta-hydroxylated derivative of phenylalanine. The D-form of dihydroxyphenylalanine has less physiologic activity than the L-form and is commonly used experimentally to determine whether the pharmacological effects of LEVODOPA are stereospecific.

Top Publications

  1. Hardy O, Hernandez Pampaloni M, Saffer J, Scheuermann J, Ernst L, Freifelder R, et al. Accuracy of [18F]fluorodopa positron emission tomography for diagnosing and localizing focal congenital hyperinsulinism. J Clin Endocrinol Metab. 2007;92:4706-11 pubmed
    ..This study evaluated the accuracy of 18F-fluoro-l-dihydroxyphenylalanine ([18F]DOPA) positron emission tomography (PET) scans in diagnosing focal vs...
  2. Rischke H, Benz M, Wild D, Mix M, Dumont R, Campbell D, et al. Correlation of the genotype of paragangliomas and pheochromocytomas with their metabolic phenotype on 3,4-dihydroxy-6-18F-fluoro-L-phenylalanin PET. J Nucl Med. 2012;53:1352-8 pubmed publisher
    ..Furthermore, we assessed whether the genotypes of pheochromocytomas and paragangliomas correlate with the uptake of (18)F-DOPA...
  3. Lacombe E, Carcenac C, Boulet S, Feuerstein C, Bertrand A, Poupard A, et al. High-frequency stimulation of the subthalamic nucleus prolongs the increase in striatal dopamine induced by acute l-3,4-dihydroxyphenylalanine in dopaminergic denervated rats. Eur J Neurosci. 2007;26:1670-80 pubmed
    ..It results in clinical improvement in patients with PD, further reducing the l-3,4-dihydroxyphenylalanine (L-DOPA) requirement and thus L-DOPA-induced dyskinesia...
  4. Marzola M, Pelizzo M, Ferdeghini M, Toniato A, Massaro A, Ambrosini V, et al. Dual PET/CT with (18)F-DOPA and (18)F-FDG in metastatic medullary thyroid carcinoma and rapidly increasing calcitonin levels: Comparison with conventional imaging. Eur J Surg Oncol. 2010;36:414-21 pubmed publisher
    ..To evaluate the role of a multi-imaging PET with (18)F-DOPA and (18)F-FDG in comparison with conventional imaging (CI) in recurrent medullary thyroid carcinoma (MTC)...
  5. Soussan M, Nataf V, Kerrou K, Grahek D, Pascal O, Talbot J, et al. Added value of early 18F-FDOPA PET/CT acquisition time in medullary thyroid cancer. Nucl Med Commun. 2012;33:775-9 pubmed publisher
    ..The only false-positive case, a reactive lymph node, was visible only on the delayed acquisition. Early acquisition appeared to be more appropriate in the detection of MTC lesions compared with acquisition at 60 min or later...
  6. Dubois S, Morel O, Rodien P, Illouz F, Girault S, Cahouet A, et al. A Pulmonary adrenocorticotropin-secreting carcinoid tumor localized by 6-Fluoro-[18F]L-dihydroxyphenylalanine positron emission/computed tomography imaging in a patient with Cushing's syndrome. J Clin Endocrinol Metab. 2007;92:4512-3 pubmed
  7. Montravers F, Kerrou K, Nataf V, Huchet V, Lotz J, Ruszniewski P, et al. Impact of fluorodihydroxyphenylalanine-18F positron emission tomography on management of adult patients with documented or occult digestive endocrine tumors. J Clin Endocrinol Metab. 2009;94:1295-301 pubmed publisher
    ..This study was conducted to evaluate the impact of FDOPA-PET on the management of patients referred for carcinoid or noncarcinoid digestive tumors and the clinical relevance of the treatment decisions based on this examination...
  8. Haug A, Auernhammer C, Wängler B, Tiling R, Schmidt G, Goke B, et al. Intraindividual comparison of 68Ga-DOTA-TATE and 18F-DOPA PET in patients with well-differentiated metastatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2009;36:765-70 pubmed publisher
    ..To compare the diagnostic impact of (68)Ga-DOTA-TATE and (18)F-DOPA PET in the diagnosis of well-differentiated metastatic neuroendocrine tumours (NET)...
  9. Koopmans K, de Groot J, Plukker J, de Vries E, Kema I, Sluiter W, et al. 18F-dihydroxyphenylalanine PET in patients with biochemical evidence of medullary thyroid cancer: relation to tumor differentiation. J Nucl Med. 2008;49:524-31 pubmed publisher
    ..Therefore, the value of 18F-dihydroxyphenylalanine PET (18F-DOPA PET), 18F-FDG PET, (99m)Tc-V-di-mercaptosulfuricacid (DMSA-V) scintigraphy, and MRI or CT ..

More Information

Publications62

  1. Kao C, Hsu W, Xie H, Lin M, Lan W, Chao H. GMP production of [18F]FDOPA and issues concerning its quality analyses as in USP "Fluorodopa F 18 Injection". Ann Nucl Med. 2011;25:309-16 pubmed publisher
    ..This paper describes the approaches for the GMP production of FDOPA and for the product testing to meet the standard of United States Pharmacopeia (USP) "Fluorodopa F 18 Injection."..
  2. Wu Chou Y, Yeh T, Wang C, Lin J, Huang C, Chang H, et al. High frequency of multiexonic deletion of the GCH1 gene in a Taiwanese cohort of dopa-response dystonia. Am J Med Genet B Neuropsychiatr Genet. 2010;153B:903-8 pubmed publisher
    ..By dosage analysis, we were able to detect a mutation in all patients. Our study demonstrates that dosage analysis is necessary for molecular diagnostics in DRD patients of Han Chinese ethnicity...
  3. Luster M, Karges W, Zeich K, Pauls S, Verburg F, Dralle H, et al. Clinical value of 18-fluorine-fluorodihydroxyphenylalanine positron emission tomography/computed tomography in the follow-up of medullary thyroid carcinoma. Thyroid. 2010;20:527-33 pubmed publisher
    ..The aim of this study was therefore to test the hypothesis that combined (18)F-DOPA PET/CT more accurately detects MTC lesions than each modality does alone...
  4. Imani F, Agopian V, Auerbach M, Walter M, Imani F, Benz M, et al. 18F-FDOPA PET and PET/CT accurately localize pheochromocytomas. J Nucl Med. 2009;50:513-9 pubmed publisher
    ..Herein, we investigated the accuracy of PET using 3,4-dihydroxy-6-(18)F-fluoro-phenylalanine ((18)F-FDOPA), an amino acid transporter substrate, as an independent marker for detection of benign and malignant pheochromocytomas...
  5. Beheshti M, Pöcher S, Vali R, Waldenberger P, Broinger G, Nader M, et al. The value of 18F-DOPA PET-CT in patients with medullary thyroid carcinoma: comparison with 18F-FDG PET-CT. Eur Radiol. 2009;19:1425-34 pubmed publisher
  6. Howes O, Montgomery A, Asselin M, Murray R, Valli I, Tabraham P, et al. Elevated striatal dopamine function linked to prodromal signs of schizophrenia. Arch Gen Psychiatry. 2009;66:13-20 pubmed publisher
  7. Fiebrich H, de Jong J, Kema I, Koopmans K, Sluiter W, Dierckx R, et al. Total 18F-dopa PET tumour uptake reflects metabolic endocrine tumour activity in patients with a carcinoid tumour. Eur J Nucl Med Mol Imaging. 2011;38:1854-61 pubmed publisher
    Positron emission tomography (PET) using 6-[18F]fluoro-L-dihydroxyphenylalanine (18F-dopa) has an excellent sensitivity to detect carcinoid tumour lesions...
  8. Treglia G, Castaldi P, Villani M, Perotti G, de Waure C, Filice A, et al. Comparison of 18F-DOPA, 18F-FDG and 68Ga-somatostatin analogue PET/CT in patients with recurrent medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2012;39:569-80 pubmed publisher
    ..To retrospectively evaluate and compare (18)F-FDG, (18)F-DOPA and (68)Ga-somatostatin analogues for PET/CT in patients with residual/recurrent medullary thyroid carcinoma (MTC) suspected on the basis of elevated serum calcitonin levels...
  9. Lopci E, D Ambrosio D, Nanni C, Chiti A, Pession A, Marengo M, et al. Feasibility of carbidopa premedication in pediatric patients: a pilot study. Cancer Biother Radiopharm. 2012;27:729-33 pubmed publisher
    ..To verify the potential role and feasibility of carbidopa premedication in pediatric patients undergoing ¹?F-DOPA (Fluorine-18 fluorodihydroxyphenylalanine) PET scanning...
  10. Di Candia S, Gessi A, Pepe G, Sogno Valin P, Mangano E, Chiumello G, et al. Identification of a diffuse form of hyperinsulinemic hypoglycemia by 18-fluoro-L-3,4 dihydroxyphenylalanine positron emission tomography/CT in a patient carrying a novel mutation of the HADH gene. Eur J Endocrinol. 2009;160:1019-23 pubmed publisher
    ..application of positron emission tomography (PET)/computed tomography (CT) scanning with 18-fluoro-l-3,4 dihydroxyphenylalanine improved the ability to distinguish the two histopathologic forms of HI (focal and diffuse), whose ..
  11. Chondrogiannis S, Grassetto G, Marzola M, Rampin L, Massaro A, Bellan E, et al. 18F-DOPA PET/CT biodistribution consideration in 107 consecutive patients with neuroendocrine tumours. Nucl Med Commun. 2012;33:179-84 pubmed publisher
    L-6-fluoro 3,4-dihydroxyphenylalanine (18F-DOPA), an amino acid-based radiopharmaceutical, is increasingly being used in the detection and management of neuroendocrine tumours...
  12. Capito C, Khen Dunlop N, Ribeiro M, Brunelle F, Aigrain Y, Cretolle C, et al. Value of 18F-fluoro-L-dopa PET in the preoperative localization of focal lesions in congenital hyperinsulinism. Radiology. 2009;253:216-22 pubmed publisher
  13. Usha R, Rajaram A, Ramasami T. Stability of collagen in the presence of 3,4-dihydroxyphenylalanine (DOPA). J Photochem Photobiol B. 2009;97:34-9 pubmed publisher
    ..L-DOPA (3,4-dihydroxyphenylalanine), a neurotransmitter, is a naturally present compound in the living system and is the target in ..
  14. Weisbrod A, Kitano M, Gesuwan K, Millo C, Herscovitch P, Nilubol N, et al. Clinical utility of functional imaging with ¹?F-FDOPA in Von Hippel-Lindau syndrome. J Clin Endocrinol Metab. 2012;97:E613-7 pubmed publisher
    ..There are limited data on the clinical utility of using ¹?F-FDOPA PET for identifying neuroendocrine tumors in a high-risk population such as VHL...
  15. Jager P, Chirakal R, Marriott C, Brouwers A, Koopmans K, Gulenchyn K. 6-L-18F-fluorodihydroxyphenylalanine PET in neuroendocrine tumors: basic aspects and emerging clinical applications. J Nucl Med. 2008;49:573-86 pubmed publisher
    ..In the remaining conditions, the initial experience with 18F-DOPA PET indicates that it seems to be less valuable, but further study is required...
  16. Schalin Jantti C, Ahonen A, Seppanen M. 18F-DOPA PET/CT but not 68Ga-DOTA-TOC PET/CT revealed the underlying cause of ectopic Cushing syndrome. Clin Nucl Med. 2012;37:904-5 pubmed publisher
    ..Ga-DOTA-TOC PET/CT, which is recommended as the first-line PET imaging, was performed, but it was not diagnostic. Imaging with F-DOPA PET/CT revealed the underlying cause...
  17. Barthlen W, Blankenstein O, Mau H, Koch M, Höhne C, Mohnike W, et al. Evaluation of [18F]fluoro-L-DOPA positron emission tomography-computed tomography for surgery in focal congenital hyperinsulinism. J Clin Endocrinol Metab. 2008;93:869-75 pubmed
    ..In congenital hyperinsulinism (CHI), the identification and precise localization of a focal lesion is essential for successful surgery...
  18. Treglia G, Cocciolillo F, Di Nardo F, Poscia A, de Waure C, Giordano A, et al. Detection rate of recurrent medullary thyroid carcinoma using fluorine-18 dihydroxyphenylalanine positron emission tomography: a meta-analysis. Acad Radiol. 2012;19:1290-9 pubmed publisher
    ..of this study was to perform a meta-analysis of published data about the diagnostic performance of (18)F-dihydroxyphenylalanine (DOPA) positron emission tomography (PET) or PET/computed tomography (CT) in detecting recurrent medullary ..
  19. Fiebrich H, Brouwers A, Koopmans K, de Vries E. Combining 6-fluoro-[18F]l-dihydroxyphenylalanine and [18F]fluoro-2-deoxy-d-glucose positron emission tomography for distinction of non-carcinoid malignancies in carcinoid patients. Eur J Cancer. 2009;45:2312-5 pubmed publisher
    ..Distinguishing a SPM from carcinoid lesions is therefore important. Differentiation can be achieved using the difference in uptake between different positron emission tomography (PET) tracers...
  20. Timmers H, Chen C, Carrasquillo J, Whatley M, Ling A, Havekes B, et al. Comparison of 18F-fluoro-L-DOPA, 18F-fluoro-deoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma. J Clin Endocrinol Metab. 2009;94:4757-67 pubmed publisher
    ..positron emission tomography (PET) agents are available for the localization of paraganglioma (PGL), including (18)F-3,4-dihydroxyphenylalanine (DOPA), (18)F-fluoro-2-deoxy-D-glucose ((18)F-FDG), and (18)F-fluorodopamine ((18)F-FDA).
  21. Gold S, Hoang C, Potts B, Porras G, Pioli E, Kim K, et al. RGS9-2 negatively modulates L-3,4-dihydroxyphenylalanine-induced dyskinesia in experimental Parkinson's disease. J Neurosci. 2007;27:14338-48 pubmed
    ..However, the findings also suggest that increasing RGS9-2 expression and/or function in PD patients may only be a suitable therapeutic strategy to control involuntary movements induced by nonselective DA agonist such as L-dopa...
  22. Umanah G, Huang L, Ding F, Arshava B, Farley A, Link A, et al. Identification of residue-to-residue contact between a peptide ligand and its G protein-coupled receptor using periodate-mediated dihydroxyphenylalanine cross-linking and mass spectrometry. J Biol Chem. 2010;285:39425-36 pubmed publisher
    ..The Trp(1) residue of ?-factor was replaced by 3,4-dihydroxyphenylalanine (DOPA) for periodate-mediated chemical cross-linking, and biotin was conjugated to Lys(7) for detection ..
  23. Zani A, Nah S, Ron O, Totonelli G, Ismail D, Smith V, et al. The predictive value of preoperative fluorine-18-L-3,4-dihydroxyphenylalanine positron emission tomography-computed tomography scans in children with congenital hyperinsulinism of infancy. J Pediatr Surg. 2011;46:204-8 pubmed publisher
    In congenital hyperinsulinism (CHI) of infancy, the use of preoperative fluorine-18-L-3,4-dihydroxyphenylalanine-positron emission tomography-computed tomography ((18)F-DOPA-PET-CT) scan has recently been reported...
  24. Hentschel M, Rottenburger C, Boedeker C, Neumann H, Brink I. Is there an optimal scan time for 6-[F-18]fluoro-L-DOPA PET in pheochromocytomas and paragangliomas?. Clin Nucl Med. 2012;37:e24-9 pubmed publisher
    To define the appropriate scan time for fluorine-18-labeled dihydroxyphenylalanine (F-18 DOPA) PET in oncological imaging of pheochromocytomas and paragangliomas.
  25. Egerton A, Demjaha A, McGuire P, Mehta M, Howes O. The test-retest reliability of 18F-DOPA PET in assessing striatal and extrastriatal presynaptic dopaminergic function. Neuroimage. 2010;50:524-531 pubmed publisher
    ..This information can be used to optimize the experimental design of future studies investigating changes in brain dopaminergic function with 18F-DOPA...
  26. Tessonnier L, Sebag F, Ghander C, De Micco C, Reynaud R, Palazzo F, et al. Limited value of 18F-F-DOPA PET to localize pancreatic insulin-secreting tumors in adults with hyperinsulinemic hypoglycemia. J Clin Endocrinol Metab. 2010;95:303-7 pubmed publisher
    Fluorine-18-L-dihydroxyphenylalanine positron emission tomography (18F-FDOPA PET) imaging is increasingly used in the workup of neuroendocrine tumors...
  27. Zemskova M, Gundabolu B, Sinaii N, Chen C, Carrasquillo J, Whatley M, et al. Utility of various functional and anatomic imaging modalities for detection of ectopic adrenocorticotropin-secreting tumors. J Clin Endocrinol Metab. 2010;95:1207-19 pubmed publisher
    ..Because ectopic ACTH-secreting (EAS) tumors are often occult, improved imaging is needed...
  28. Yakemchuk V, Jager P, Chirakal R, Reid R, Major P, Gulenchyn K. PET/CT using ¹?F-FDOPA provides improved staging of carcinoid tumor patients in a Canadian setting. Nucl Med Commun. 2012;33:322-30 pubmed publisher
    ..This study assessed the diagnostic accuracy of 6-[¹?F]fluoro-3,4-dihydroxyphenylalanine (¹?F-FDOPA) PET/CT in neuroendocrine tumors.
  29. Ambrosini V, Tomassetti P, Castellucci P, Campana D, Montini G, Rubello D, et al. Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours. Eur J Nucl Med Mol Imaging. 2008;35:1431-8 pubmed publisher
    ..At present, there are no comparative studies investigating their role in NET...
  30. Zeng H, Hwang D, Israelachvili J, Waite J. Strong reversible Fe3+-mediated bridging between dopa-containing protein films in water. Proc Natl Acad Sci U S A. 2010;107:12850-3 pubmed publisher
    ..Mfp-1, containing 13 mol % of dopa (3, 4-dihydroxyphenylalanine) side-chains, is highly positively charged polyelectrolyte (pI approximately 10) and didn't show any ..
  31. Sharov V, Dremina E, Pennington J, Killmer J, Asmus C, Thorson M, et al. Selective fluorogenic derivatization of 3-nitrotyrosine and 3,4-dihydroxyphenylalanine in peptides: a method designed for quantitative proteomic analysis. Methods Enzymol. 2008;441:19-32 pubmed publisher
    ..a method for the selective derivatization of 3-nitrotyrosine (after reduction to 3-amino-tyrosine) and 3,4-dihydroxyphenylalanine with benzylamine derivatives to yield 6-amino- and 6-benzylamine-substituted benzoxazoles, which display ..
  32. Mackenzie I, Gurnell M, Balan K, Simpson H, Chatterjee K, Brown M. The use of 18-fluoro-dihydroxyphenylalanine and 18-fluorodeoxyglucose positron emission tomography scanning in the assessment of metaiodobenzylguanidine-negative phaeochromocytoma. Eur J Endocrinol. 2007;157:533-7 pubmed
    ..of phaeochromocytoma, but who had negative 123I-MIBG scans, and illustrate the usefulness of 18-fluoro-dihydroxyphenylalanine PET scanning in their assessment...
  33. Visanji N, Fox S, Johnston T, Millan M, Brotchie J. Alpha1-adrenoceptors mediate dihydroxyphenylalanine-induced activity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaques. J Pharmacol Exp Ther. 2009;328:276-83 pubmed publisher
    The mechanisms underlying actions of dihydroxyphenylalanine (L-DOPA) in Parkinson's disease remain to be fully elucidated. Noradrenaline formed from L-DOPA may stimulate alpha(1)-adrenoceptors...
  34. Mohnike K, Blankenstein O, Minn H, Mohnike W, Fuchtner F, Otonkoski T. [18F]-DOPA positron emission tomography for preoperative localization in congenital hyperinsulinism. Horm Res. 2008;70:65-72 pubmed publisher
    ..Fluorine-18 L-3,4-dihydroxyphenylalanine positron emission tomography ((18)F-DOPA-PET) has been introduced for differentiation between focal and ..
  35. Masue M, Nishibori H, Fukuyama S, Yoshizawa A, Okamoto S, Doi R, et al. Diagnostic accuracy of [¹?F]-fluoro-L-dihydroxyphenylalanine positron emission tomography scan for persistent congenital hyperinsulinism in Japan. Clin Endocrinol (Oxf). 2011;75:342-6 pubmed publisher
    We aimed to elucidate the accuracy and limitations of [(18)F]-fluoro-L-dihydroxyphenylalanine ([(18) F]DOPA) positron emission tomography (PET) for Japanese patients with congenital hyperinsulinism...
  36. Schiepers C, Chen W, Cloughesy T, Dahlbom M, Huang S. 18F-FDOPA kinetics in brain tumors. J Nucl Med. 2007;48:1651-61 pubmed
    ..Evaluation of tumor recurrence in neurooncology is another application. Here, the kinetics of (18)F-FDOPA in brain tumors were investigated...
  37. Fueger B, Czernin J, Cloughesy T, Silverman D, Geist C, Walter M, et al. Correlation of 6-18F-fluoro-L-dopa PET uptake with proliferation and tumor grade in newly diagnosed and recurrent gliomas. J Nucl Med. 2010;51:1532-8 pubmed publisher
    ..The aims of the current study were to determine whether the degree of (18)F-FDOPA uptake in brain tumors predicted tumor grade and was associated with tumor proliferative activity in newly diagnosed and recurrent gliomas...
  38. Fottner C, Helisch A, Anlauf M, Rossmann H, Musholt T, Kreft A, et al. 6-18F-fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to 123I-metaiodobenzyl-guanidine scintigraphy in the detection of extraadrenal and hereditary pheochromocytomas and paragangliomas: correlation with vesicular monoamine tr. J Clin Endocrinol Metab. 2010;95:2800-10 pubmed publisher
    ..Pheochromocytomas (PHEOs) and paragangliomas (PGLs) may be better detected by (18)F-fluorodihydroxyphenylalanine-positron emission tomography (FDOPA-PET) than (123)I-metaiodobenzyl-guanidine (123-I-MIBG) scintigraphy...
  39. Verbeek H, Plukker J, Koopmans K, de Groot J, Hofstra R, Muller Kobold A, et al. Clinical relevance of 18F-FDG PET and 18F-DOPA PET in recurrent medullary thyroid carcinoma. J Nucl Med. 2012;53:1863-71 pubmed publisher
    ..We compared (18)F-FDG PET and (18)F-dihydroxyphenylanaline ((18)F-DOPA) PET with biochemical parameters and survival to assess whether these imaging modalities could be of value in detecting progressive disease...
  40. Treglia G, Mirk P, Giordano A, Rufini V. Diagnostic performance of fluorine-18-dihydroxyphenylalanine positron emission tomography in diagnosing and localizing the focal form of congenital hyperinsulinism: a meta-analysis. Pediatr Radiol. 2012;42:1372-9 pubmed publisher
    We performed a meta-analysis on published data on the diagnostic performance of fluorine-18 dihydroxyphenylalanine ((18)F-DOPA) positron emission tomography (PET) in diagnosing and localizing focal congenital hyperinsulinism (CHI).
  41. Koopmans K, Neels O, Kema I, Elsinga P, Sluiter W, Vanghillewe K, et al. Improved staging of patients with carcinoid and islet cell tumors with 18F-dihydroxy-phenyl-alanine and 11C-5-hydroxy-tryptophan positron emission tomography. J Clin Oncol. 2008;26:1489-95 pubmed publisher
    ..To evaluate and compare diagnostic sensitivity of positron emission tomography (PET) scanning in carcinoid and islet cell tumor patients with a serotonin and a catecholamine precursor as tracers...
  42. Ribeiro M, Boddaert N, Bellanne Chantelot C, Bourgeois S, Valayannopoulos V, Delzescaux T, et al. The added value of [18F]fluoro-L-DOPA PET in the diagnosis of hyperinsulinism of infancy: a retrospective study involving 49 children. Eur J Nucl Med Mol Imaging. 2007;34:2120-8 pubmed
    ..Here, we report the diagnostic value of PET with [(18)F]fluoro-L-DOPA in distinguishing focal from diffuse HI...
  43. Kauhanen S, Schalin Jantti C, Seppanen M, Kajander S, Virtanen S, Schildt J, et al. Complementary roles of 18F-DOPA PET/CT and 18F-FDG PET/CT in medullary thyroid cancer. J Nucl Med. 2011;52:1855-63 pubmed publisher
    ..Our aim was to compare fluorine-labeled dihydroxyphenylalanine ((18)F-DOPA) and (18)F-FDG PET/CT with multidetector CT (MDCT) and MRI in recurrent or persistent MTC.
  44. Putzer D, Gabriel M, Kendler D, Henninger B, Knoflach M, Kroiss A, et al. Comparison of (68)Ga-DOTA-Tyr(3)-octreotide and (18)F-fluoro-L-dihydroxyphenylalanine positron emission tomography in neuroendocrine tumor patients. Q J Nucl Med Mol Imaging. 2010;54:68-75 pubmed
    68)Ga-DOTA-Tyr3-octreotide positron emission tomography ((68)Ga-DOTA-TOC PET) and (18)F-fluoro-L-dihydroxyphenylalanine PET ((18)F-DOPA PET) are emerging modalities for imaging of neuroendocrine tumors...
  45. King K, Chen C, Alexopoulos D, Whatley M, Reynolds J, Patronas N, et al. Functional imaging of SDHx-related head and neck paragangliomas: comparison of 18F-fluorodihydroxyphenylalanine, 18F-fluorodopamine, 18F-fluoro-2-deoxy-D-glucose PET, 123I-metaiodobenzylguanidine scintigraphy, and 111In-pentetreotide scintigraphy. J Clin Endocrinol Metab. 2011;96:2779-85 pubmed publisher
    ..Accurate diagnosis of head and neck paragangliomas is often complicated by biochemical silence and lack of catecholamine-associated symptoms, making accurate anatomical and functional imaging techniques essential to the diagnostic process...
  46. Taieb D, Tessonnier L, Sebag F, Niccoli Sire P, Morange I, Colavolpe C, et al. The role of 18F-FDOPA and 18F-FDG-PET in the management of malignant and multifocal phaeochromocytomas. Clin Endocrinol (Oxf). 2008;69:580-6 pubmed publisher
    ..18)F-DOPA has emerged as a promising tool in the localization of chromaffin-tissue-derived tumours. Interestingly, phaeochromocytomas (PHEO) are also FDG avid...
  47. Segawa M. Dopa-responsive dystonia. Handb Clin Neurol. 2011;100:539-57 pubmed publisher
    ..In recessive disorders, hypofunction of serotonin and noradrenaline induces hypofunction of the dopamine in the perikaryon and shows cortical dysfunction...
  48. Treglia G, Cocciolillo F, de Waure C, Di Nardo F, Gualano M, Castaldi P, et al. Diagnostic performance of 18F-dihydroxyphenylalanine positron emission tomography in patients with paraganglioma: a meta-analysis. Eur J Nucl Med Mol Imaging. 2012;39:1144-53 pubmed publisher
    ..The aim of this study was to systematically review and conduct a meta-analysis of published data about the diagnostic performance of (18)F-dihydroxyphenylalanine (DOPA) positron emission tomography (PET) in patients with paraganglioma (PG).
  49. Lee H, Dellatore S, Miller W, Messersmith P. Mussel-inspired surface chemistry for multifunctional coatings. Science. 2007;318:426-30 pubmed
  50. Rufini V, Treglia G, Castaldi P, Perotti G, Calcagni M, Corsello S, et al. Comparison of 123I-MIBG SPECT-CT and 18F-DOPA PET-CT in the evaluation of patients with known or suspected recurrent paraganglioma. Nucl Med Commun. 2011;32:575-82 pubmed publisher
    ..single-photon emission computed tomography (SPECT) computed tomography (CT) scanning] and fluorine-18-L-dihydroxyphenylalanine positron emission tomography CT (18F-DOPA PET-CT) in the re-staging of patients with known or suspected ..
  51. Fiebrich H, Brouwers A, Kerstens M, Pijl M, Kema I, de Jong J, et al. 6-[F-18]Fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to conventional imaging with (123)I-metaiodobenzylguanidine scintigraphy, computer tomography, and magnetic resonance imaging in localizing tumors causing catecholamine . J Clin Endocrinol Metab. 2009;94:3922-30 pubmed publisher
    ..Catecholamine excess is rare, but symptoms may be life threatening...
  52. Luster M, Karges W, Zeich K, Pauls S, Verburg F, Dralle H, et al. Clinical value of 18F-fluorodihydroxyphenylalanine positron emission tomography/computed tomography (18F-DOPA PET/CT) for detecting pheochromocytoma. Eur J Nucl Med Mol Imaging. 2010;37:484-93 pubmed publisher
    ..The aim of this study was to investigate whether combined (18)F-DOPA PET/CT more accurately detects and localizes PHEO lesions than does each modality alone...
  53. Timmers H, Hadi M, Carrasquillo J, Chen C, Martiniova L, Whatley M, et al. The effects of carbidopa on uptake of 6-18F-Fluoro-L-DOPA in PET of pheochromocytoma and extraadrenal abdominal paraganglioma. J Nucl Med. 2007;48:1599-606 pubmed
    6-(18)F-fluoro-l-3,4-dihydroxyphenylalanine ((18)F-DOPA) PET is a useful tool for the detection of certain neuroendocrine tumors, especially with the preadministration of carbidopa, an inhibitor of DOPA decarboxylase...